Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Weekly Doses of Palifermin (rHuKGF) for the Reduction of Oral Mucositis in Subjects With Advanced Head and Neck Cancer Receiving Radiotherapy With Concurrent Chemotherapy (RT/CT)
The purpose of this research study is to test the safety and effectiveness of palifermin to determine if weekly doses can be safely administered to reduce the incidence (occurrence of), duration (length of time) and severity (amount of pain) of oral mucositis (painful sores in the mouth). Mucositis is a common side effect for patients receiving chemotherapy (cancer-killing drug) and radiotherapy (cancer-killing x-rays) for the treatment of head and neck cancer (HNC).
Stanford is not currently accepting new patients for this trial. You may want to check clinicaltrials.gov to see if other locations are recruiting.
- drug : Placebo
- drug : Palifermin
- drug : cisplatin chemotherapy
- radiation : Radiotherapy
Phase: Phase 3
Ages Eligible For Study:
- Histologically documented squamous cell carcinoma involving either the oral cavity, oropharynx, nasopharynx, hypopharynx, or larynx - Newly diagnosed, locally advanced stage head and neck cancer (unresectable/unresected disease); American Joint Committee on Cancer [AJCC] Stage III, IVA or IVB amenable to radiotherapy with concurrent chemotherapy as the definitive treatment modality - At least 50 Gray of radiation treatment to areas of the oral cavity/oropharynx mucosa that can be visualized - Concurrent chemotherapy regimen of Cisplatin 100mg/m^2 on days 1, 22, and 43 - Eastern Cooperative Oncology Group (ECOG) performance status (PS) less than or equal to 2 - Adequate hematologic, renal and hepatic function - Negative pregnancy test by serum or urine - Signed informed consent Key